Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 14, 2024 07:30 ET | Source: Veralox Therapeutics

Veralox Therapeutics Announces EMA Orphan Drug Designation for VLX-1005

Veralox Therapeutics Announces EMA Orphan Drug Designation for VLX-1005
June 20, 2023 07:00 ET | Source: Veralox Therapeutics

Veralox Names Jonathan Mow as Chief Executive Officer as the Company Advances Development of First-in-Class Therapies for Immune-Mediated Diseases in Conjunction with Financing

-- New Financing of $24 Million Fully Funds the Phase 2 Clinical Program for Lead Candidate VLX-1005 -- Company Prepares to Evaluate VLX-1005 in Heparin-Induced Thrombocytopenia (HIT) FREDERICK,...